Početna stranicaALMKT • EPA
add
Mauna Kea Technologies SA
Preth. zaklj. cijena
0,18 €
Dnevni raspon
0,17 € - 0,18 €
Godišnji raspon
0,16 € - 0,53 €
Tržišna kapitalizacija
11,36 mil. EUR
Prosječna količina
101,42 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
EPA
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (EUR) | lip 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 2,13 mil. | −40,22 % |
Operativni troškovi | 3,51 mil. | −5,78 % |
Neto dohodak | −2,34 mil. | −267,42 % |
Neto profitabilnost | −109,77 | −380,03 % |
Zarada po dionici | — | — |
EBITDA | −1,76 mil. | −559,07 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (EUR) | lip 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 3,82 mil. | −39,56 % |
Ukupna imovina | 18,15 mil. | −25,14 % |
Ukupne obveze | 38,49 mil. | −5,23 % |
Ukupni kapital | −20,34 mil. | — |
Dionice u optjecaju | 64,62 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | −0,56 | — |
Povrat imovine | −25,45 % | — |
Povrat kapitala | −56,78 % | — |
Tok novca
Neto promjena novca
| (EUR) | lip 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −2,34 mil. | −267,42 % |
Gotovina od poslovanja | −1,90 mil. | −233,29 % |
Gotovina iz ulaganja | 36,50 tis. | 183,91 % |
Gotovina iz financiranja | −226,50 tis. | −218,90 % |
Neto promjena novca | −2,09 mil. | −232,96 % |
Slobodan tok novca | −802,94 tis. | −487,16 % |
Više
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Glavni izvršni direktor
Osnovano
2000
Web-lokacija
Zaposlenici
65
